Treatment of agoraphobia with group exposure in vivo and imipramine
- PMID: 6101535
- DOI: 10.1001/archpsyc.1980.01780140065007
Treatment of agoraphobia with group exposure in vivo and imipramine
Abstract
Seventy-six white agoraphobic women, 21 to 45 years old, were treated with combined group exposure in vivo and imipramine or placebo in a randomized double-blind study. A majority of the patients in both the placebo and imipramine groups showed moderate to marked improvement. However, imipramine therapy was significantly superior to placebo therapy on three of the four reported measures of improvement: primary phobia, spontaneous panic, and global improvement. There was a negative correlation between depression and outcome; ie, the more depressed patients fared worse on several outcome measures than those who were less depressed. A comparison of these patients with agoraphobic women previously treated with imipramine and imaginal desensitization showed a superiority of exposure in vivo midway in treatment, but no significant difference between the two groups at the completion of therapy.
Similar articles
-
Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo.Arch Gen Psychiatry. 1983 Feb;40(2):125-38. doi: 10.1001/archpsyc.1983.01790020019002. Arch Gen Psychiatry. 1983. PMID: 6337578 Clinical Trial.
-
Panic and avoidance in agoraphobia. Application of path analysis to treatment studies.Arch Gen Psychiatry. 1987 Apr;44(4):377-85. doi: 10.1001/archpsyc.1987.01800160093011. Arch Gen Psychiatry. 1987. PMID: 2882736 Clinical Trial.
-
Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.Br J Psychiatry. 1983 Oct;143:348-55. doi: 10.1192/bjp.143.4.348. Br J Psychiatry. 1983. PMID: 6626853 Clinical Trial.
-
Differential effects of imipramine and behavior therapy on panic disorder with agoraphobia.Psychopharmacol Bull. 1989;25(1):27-9. Psychopharmacol Bull. 1989. PMID: 2672069 Review. No abstract available.
-
Antidepressant medication in the treatment of agoraphobia: a critical review.Behav Res Ther. 1983;21(5):505-17. doi: 10.1016/0005-7967(83)90042-6. Behav Res Ther. 1983. PMID: 6140001 Review. No abstract available.
Cited by
-
A risk-benefit assessment of buspirone in the treatment of anxiety disorders.Drug Saf. 1997 Feb;16(2):118-32. doi: 10.2165/00002018-199716020-00004. Drug Saf. 1997. PMID: 9067123 Review.
-
Differential diagnosis and treatment of the "housebound syndrome".Can Med Assoc J. 1984 Nov 1;131(9):1041-4. Can Med Assoc J. 1984. PMID: 6498716 Free PMC article.
-
Panic control treatment and its applications.J Psychother Pract Res. 1999 Winter;8(1):3-11. J Psychother Pract Res. 1999. PMID: 9888103 Free PMC article. Review.
-
Urinary norepinephrine excretion in panic and phobic disorders.J Neural Transm. 1986;65(1):75-81. doi: 10.1007/BF01249613. J Neural Transm. 1986. PMID: 3958707
-
Nonpharmacological treatments for anxiety disorders.Dialogues Clin Neurosci. 2002 Sep;4(3):305-19. doi: 10.31887/DCNS.2002.4.3/jcottraux. Dialogues Clin Neurosci. 2002. PMID: 22034140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical